Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPID | Q08752 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117148 | 0.81 | PPID (0.50) | TACR1ESR1KCNH2TP53POLB | |
| SCHEMBL5125017 | 0.79 | NOS2 (0.42) | TACR1 | |
| SCHEMBL13013230 | 0.78 | TP53 (0.52) | TACR1TP53TSHRPOLB | |
| SCHEMBL5118162 | 0.76 | NLRP3 (0.47) | TACR1TP53POLB | |
| SCHEMBL7276676 | 0.75 | ALDH1A1 (0.46) | ESR1SMN1; SMN2POLB | |
| SCHEMBL3310634 | 0.74 | TACR1 (0.44) | TACR1TP53POLBPPID | |
| SCHEMBL3316803 | 0.74 | TACR1 (0.44) | TACR1TP53POLBPPID | |
| Hydrochloric Acid SCHEMBL5117084 | 0.74 | PRSS1 (0.41) | TSHR | |
| SCHEMBL8731461 | 0.73 | THRB (0.51) | PTGS2TSHRSMN1; SMN2POLB | |
| SCHEMBL31689496 | 0.72 | CTSL (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959918-B1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J PHARMA CO LTD (JP) | 2019-05-22 | — | — | EP | disclosed |
| US-10172835-B2 | Anticancer agent composition | J-PHARMA CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | J-PHARMA CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-2959918-A1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J-Pharma Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-1481965-B1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | ENDO HITOSHI (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-7345068-B2 | Aromatic amino acid derivatives and medicinal compositions | Endou, Hitoshi (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | HITOSHI ENDOU (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1481965-A1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | Endo, Hitoshi (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | TUBB1, TUBA1A, TUBA1C | TACR1 4322/4885ESR1 2008/4885KCNH2 4880/4885 |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | SLC7A1, SLC1A5, SLC7A5 | TACR1 1485/4885ESR1 2959/4885KCNH2 2669/4885 |
| US-10172835-B2 | Anticancer agent composition | TOP1, TUBB1, TUBA1A | TACR1 4329/4885ESR1 2214/4885KCNH2 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.